Kisspeptin-10

Kisspeptin-10 is the C-terminal decapeptide fragment of kisspeptin, the peptide product of the KISS1 gene and the shortest fragment that retains full receptor activity. It binds the G-protein-coupled receptor KISS1R (formerly GPR54) on hypothalamic neurons that produce gonadotropin-releasing hormone (GnRH). Receptor activation drives GnRH secretion into the hypophyseal portal system, which in turn stimulates pituitary release of luteinizing hormone (LH) and, to a lesser degree, follicle-stimulating hormone (FSH), placing kisspeptin signaling at the top of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin neurons integrate sex-steroid feedback and metabolic signals, and human imaging work suggests kisspoptin also modulates limbic circuits involved in sexual and emotional processing. Its plasma half-life is only a few minutes, so effects are transient.

Human physiology studies are substantial for an investigational peptide. Jayasena et al. (2011) showed that kisspeptin-10 stimulates LH release with marked sexual dimorphism and menstrual-cycle-phase dependence. The longer kisspeptin-54 isoform has been tested as an oocyte-maturation 'trigger' in IVF (Abbara et al., 2015), and Mills et al. (2023) reported that kisspeptin modulated sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder. Despite these signals, kisspeptin remains an experimental agent: no formulation is approved for any indication, trials are small and short-term, and long-term safety data are lacking.

Educational overview only — no dosing instructions in the public hub.

Human safety beyond short experimental exposures is not established, and there is no approved product with a defined safety profile. The very short half-life makes sustained effects difficult and desensitization of KISS1R signaling is a theoretical concern with continuous exposure. Because kisspeptin sits atop the reproductive axis, off-label use could perturb menstrual cyclicity, ovulation, or gonadotropin balance in unpredictable ways. For material sold outside clinical trials, the dominant practical risks are unverified identity, purity, and endotoxin content rather than any characterized pharmacologic hazard.

Kisspeptin-10 sold as 'research use only' is not a medicine and carries no pharmaceutical quality assurance. A third-party certificate of analysis documenting identity, purity (HPLC), quantification, and mass-spectrometry confirmation is the minimum verification, and even that does not establish sterility or fitness for human use. Clinical-trial kisspeptin is produced under controlled conditions that gray-market material cannot be assumed to match.

Investigational / research-use-only. Kisspeptin-10 (and kisspeptin-54) are not approved as medicines by the FDA, EMA, or MHRA for any indication; human use occurs only within regulated clinical research. Products marketed 'for research use only' are not authorized for human administration.